Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 4/20 | 0.53 |
| ▸ | DEGS1 | O15121 | 3/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31241006 | 0.86 | RAB9A (0.68) | RAB9AALDH1A1NPC1SMN1; SMN2TSHR | |
| SCHEMBL2320718 | 0.85 | DEGS1 (0.43) | RAB9AALDH1A1NPC1SMN1; SMN2TSHR | |
| SCHEMBL2315751 | 0.85 | HDAC1 (0.45) | RAB9AALDH1A1NPC1SMN1; SMN2DEGS1 | |
| SCHEMBL2318170 | 0.84 | ALDH1A1 (0.55) | RAB9AALDH1A1NPC1SMN1; SMN2TSHR | |
| SCHEMBL12283692 | 0.84 | USP30 (0.55) | DEGS1USP30MEN1KMT2A | |
| SCHEMBL2318039 | 0.83 | MAPK8 (0.47) | RAB9ANPC1SMN1; SMN2TSHRUSP30 | |
| SCHEMBL31241140 | 0.83 | RAB9A (0.73) | RAB9AALDH1A1NPC1SMN1; SMN2TSHR | |
| SCHEMBL2317846 | 0.82 | ALDH1A1 (0.71) | RAB9AALDH1A1NPC1SMN1; SMN2TSHR | |
| SCHEMBL2317904 | 0.81 | DEGS1 (0.53) | DEGS1USP30 | |
| SCHEMBL2320672 | 0.81 | WNT3A (0.53) | DEGS1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102272120-A | Biologically active amides | — | 2011-12-07 | — | — | CN | disclosed |
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| EP-2352730-A2 | BIOLOGICALLY ACTIVE AMIDES | H. Lundbeck A/S (DK) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010053861-A2 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | NPY5R, NPY1R, NPY2R | RAB9A 3184/4885ALDH1A1 3024/4885NPC1 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.